Circular Therapeutic Particle Formation With Low-Void Morphology Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing circular particles lack sufficient control over size uniformity, shape selectivity, surface functionality, and skeletal density, making them unsuitable for pharmaceutical applications.
Innovation Solution
A method involving droplet formation, contact with a second liquid, and evaporation to create particles with less than 25% internal void spaces and circularity between 0.10 to 1.00, controlled by Peclet number and component solubility, enriching the first component at the surface.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to synthesize circular particles, then particle formation is achieved, but size uniformity, shape selectivity, surface functionality, and skeletal density control are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying droplet size, evaporation rate, and Peclet number to achieve precise control over particle size uniformity (span < 20%), shape circularity (0.7-1.0), and skeletal density (0.3-0.8 g/cm³). This resolves the contradiction by transforming the particle formation process into a parameter-controlled system that achieves high manufacturing precision without excessive complexity
Solution Approach 2:
The patent replaces conventional mechanical particle synthesis methods with a droplet-based evaporation system controlled by Peclet number. This substitution enables precise control over surface functionality and skeletal density through evaporative dynamics rather than mechanical processing, achieving high manufacturing precision while simplifying the overall process
2Stability of the object's composition
If internal void spaces are reduced in particles, then particle stability and density are improved, but manufacturing control becomes more difficult
Solution Approach 1:
The patent employs feedback control through monitoring and adjusting the Peclet number during the evaporation process to achieve target skeletal density ranges (0.3-0.8 g/cm³) and internal void space percentages (5-40%). This feedback mechanism enables simultaneous achievement of particle stability and manufacturing precision by dynamically controlling evaporative dynamics
Solution Approach 2:
The patent applies preliminary action by pre-establishing the droplet composition, solvent selection, and evaporation conditions before particle formation to predict and control the resulting internal structure. This preliminary configuration enables precise control over skeletal density and void space distribution, achieving both stability and manufacturing precision
3Adaptability or versatility
If component enrichment at particle surface is achieved, then surface functionality is enhanced, but internal composition uniformity may be compromised
Solution Approach 1:
The patent applies local quality by creating distinct compositional zones within particles through Peclet number-controlled evaporation. The first component enriches at the surface (10-50% higher concentration) while the internal composition remains uniform, providing enhanced surface functionality without compromising internal stability. This spatial differentiation of composition resolves the contradiction between surface adaptability and internal uniformity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the formation of stable, pharmaceutically relevant particles with enhanced stability and controlled morphology, suitable for pharmaceutical compositions and therapies.
Implementation Method 1
allowing the droplets to dry; and removing the first and second liquids
Implementation Method 2
contacting the droplets with a second liquid under a specified Peclet number; the specified Peclet number controls the morphology of the particles
Data Source
AI summary
The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.